Artificial Pancreas Device System Market Research Report–Forecast till 2030

Artificial Pancreas Device System Market Research Report by Type (CTR, CTT), End-user (Hospitals, Medical Centers, and Others), and Region (North America, Europe, APAC, RoW)- Forecast to 2030

ID: MRFR/MED/5208-HCR | February 2023 | Region: Global | 100 Pages         

Artificial Pancreas Device System Market Speak to Analyst Request a Free Sample

Artificial Pancreas Device System Market

Artificial Pancreas Device System Market is expected to reach USD 341.08 Million at CAGR of 18% during the forecast period of 2022-2030

Segmentation
By Type CTR (Control to Range) Systems CTT (Control To Target) Systems
By End Users Hospitals Medical Centers
Key Players
Companies Profiled   Medtronic Plc   Bigfoot Biomedical   Johnson & Johnson   Dexcom Inc.   Cellnovo   Tandem Diabetes Care Inc.   Pancreum Inc.   TypeZero Technologies LLC   Beta Bionics    F. Hoffmann-La Roche Ltd   Inreda Diabetic B.V.   nsulet Corp
Drivers
Market Driving Forces   Number of cases being diagnosed with diabetes   Rising inflow of investment
Request a Free Sample

Artificial Pancreas Device System Market Overview:


The need for artificial pancreas devices has recently surged as the number of instances involving pancreatic diseases and malfunctions has climbed significantly. In the projection period between 2022-2030, the market is expected to generate sales of USD 341.08 million while expanding at a CAGR of 18.0 percent. The increasing number of diabetes patients detected is a crucial driver in encouraging market expansion.


The increased infusion of investment into the industry is predicted to improve product quality, hence increasing market sales. Patients are more involved in the selection of their treatment alternatives in some circumstances now that they are more or less aware of the treatment possibilities. This aspect is expected to favorably impact the growth of the artificial pancreas device system market over the forecast period.


Report Overview


The market perspective offered by MRFR spans the entire market and gives in-depth coverage of the latest trends that are shaping the future of the artificial pancreas device system market. The report aptly captures the development of the market through current market trends, historical growth analysis, and revenue projections for a period ranging to 2023. The market also mentions CTR (Control to Range) Systems and CTT (Control to Target) Systems. The end user segments such as hospital and medical centers are also significantly emphasized upon, and a detailed analysis of the segments is also presented in the report. The market dynamics related to pricing and feasibility analysis is significantly along with macroeconomic indicators, and feasibility indicators provides a comprehensive overview of the artificial pancreas device system market in the forecast period.


Report Coverage


The report on the artificial pancreas device system market consists of market dynamics, forecast, historical market trends, market value by region as well as by country-level analysis for each market segment, segmentation, market factor analysis and key player’s market share analysis that includes supply chain and Porter’s five forces analysis of the market.


Companies Covered


Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp


Research Methodology


The progression of research while creating reports at Market Research Future includes highlights and facts that are essential to the expansion of artificial pancreas device system market. The research initiated by our analysts enhances the capability of our clients to outline their vision for growth better. The unification of primary and secondary research approaches in our reports divulges widespread information connected to new revenue pockets and developing markets globally. The report methodology also ensures strategy roadmaps that exhibit a distinct picture of the present trends as well as the trends that can affect the forthcoming development of the artificial pancreas device system market. An intrinsic level of understanding connected to the value chain in a specific market additionally contributes to the value of the reports created by our analysts. Furthermore, the insights into markets, technologies, and industry sectors is positively achieved by the application of top-down and bottom-up approaches.Recent Development


Bigfoot Biomedical is a medical device business that is revolutionizing diabetes care for patients who require insulin. The business is working on an end-to-end type 1 diabetes management system that employs a simple design, cloud connection, and human-centered automation. It improves insulin administration and delivery via an integrated medical device ecosystem powered by machine learning and augmented by secure, user-friendly consumer technology, radically altering the care paradigm.


Tandem Diabetes Care Inc (Tandem) is a medical device manufacturer that creates diabetes care devices. The t: slim X2 insulin pump, basal-IQ technology, Control-IQ technology, software and apps, infusion sets, and various pump accessories are all part of the company's product line. It also provides linked health services. It also offers product support services to assist its customers in further customizing their systems. The firm sells its products in almost all the countries such as Australia, New Zealand, South Africa, France, and Germany. Tandem's headquarters are in San Diego, California, USA.


Segmental Analysis


The segmentation of the artificial pancreas device market has been carried out to better gauge the artificial pancreas device system market.


By Type



  • CTR (Control to Range) Systems

  • CTT (Control To Target) Systems


By End User



  • Hospitals

  • Medical Centers


By Region



  • North America

  • South America

  • Europe

  • Asia-Pacific

  • Middle East

  • Africa



Report Scope:

Report Attribute/Metric Details
  Market Size   2023: 341.08 million
  CAGR   18%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, End User and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp
  Key Market Opportunities   Product Manufacturer
  Key Market Drivers

  • Number of cases being diagnosed with diabetes
  • Rising inflow of investment


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The types are included in the artificial pancreas device system market are CTR (Control to Range) Systems, CTT (Control To Target) Systems.

    The major drivers of artificial pancreas device system market are Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp.

    Artificial Pancreas Device System Market is expected to reach US 341.08 million and at a CAGR 18%% through 2030.

    The Major driving factor of Artificial Pancreas Device System Market is Number of cases being diagnosed with diabetes.